Capital Fund Management S.A. Astrazeneca PLC Call Options Transaction History

Capital Fund Management S.A.

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	BUY	$76.67 - $87.62 $1.92 Million - $2.19 Million	25,000 New	25,000 $1.95 Million
Q3 2023 Nov 14, 2023	BUY	$64.85 - $71.7 $220,489 - $243,780	3,400 Added 19.65%	20,700 $1.4 Million
Q2 2023 Aug 14, 2023	SELL	$69.91 - $75.81 $1.26 Million - $1.36 Million	-18,000 Reduced 50.99%	17,300 $1.24 Million
Q1 2023 May 15, 2023	SELL	$63.15 - $71.6 $530,460 - $601,440	-8,400 Reduced 19.22%	35,300 $2.45 Million
Q4 2022 Feb 13, 2023	SELL	$54.21 - $70.44 $2.96 Million - $3.85 Million	-54,600 Reduced 55.54%	43,700 $2.96 Million
Q3 2022 Nov 14, 2022	BUY	$53.02 - $135.75 $1.79 Million - $4.59 Million	33,800 Added 52.4%	98,300 $5.39 Billion
Q2 2022 Aug 12, 2022	BUY	$59.26 - $71.14 $2.94 Million - $3.53 Million	49,600 Added 332.89%	64,500 $4.26 Million
Q1 2022 May 12, 2022	BUY	$55.72 - $67.12 $529,340 - $637,640	9,500 Added 175.93%	14,900 $988,000
Q1 2020 May 13, 2020	SELL	$37.79 - $51.33 $75,580 - $102,660	-2,000 Reduced 27.03%	5,400 $241,000
Q4 2019 Feb 13, 2020	BUY	$42.46 - $50.46 $314,204 - $373,404	7,400 New	7,400 $369,000

1,361

475M

5.39M

3.75M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $200B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.